CATALYST PHARMACEUTICALS INC (CPRX) Stock News
NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock - Currency: USD
CPRX Latest News, Press Relases and Analysis
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A CANSLIM Candidate With Strong Growth Metrics
CATALYST PHARMACEUTICALS (CPRX) meets key CANSLIM criteria with strong earnings growth, high profitability, and market-leading relative strength. A debt-free balance sheet adds appeal.
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors
CATALYST PHARMACEUTICALS INC (CPRX) shows strong earnings growth, high profitability, and solid cash flow, making it a standout for growth investors.
Needham Bank to acquire BankProv to expand market reach
The transaction is valued at $211.8m, based on Needham's share price as of 4 June 2025.
Why Cleveland-Cliffs Stock Soared This Week
President Trump raised foreign steel tariffs to 50%, boosting American steel stocks, such as Cleveland Cliffs. Shares of Cleveland-Cliffs (NYSE: CLF) are moving higher this week, up 28.8% from last Friday's close as of 2:00 p.m. ET. The American steelmaker will benefit from President Donald Trump's new steel tariffs that went into effect earlier this week.
Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: UTHR
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Makes Catalyst Pharmaceutical (CPRX) a Strong Momentum Stock: Buy Now?
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Mentions: COR
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst (CPRX) Is a Great Choice for 'Trend' Investors, Here's Why
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career...
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of 28.30% and 8.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: DRRX
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6%...
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: XNCR
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ZTS
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage...